About AltheaDx
AltheaDx is a company based in San Diego (United States) founded in 2009 was acquired by Castle Biosciences in April 2022.. AltheaDx has raised $94.73 million across 14 funding rounds from investors including Castle Biosciences, WuXi AppTec and 6 Dimensions Capital. AltheaDx offers products and services including IDgenetix, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and DecisionDx-UM. AltheaDx operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Altheadx, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$94.73 M (USD)
in 14 rounds
-
Latest Funding Round
$3.73 M (USD), Series D
Dec 04, 2020
-
Investors
Castle Biosciences
& 5 more
-
Employee Count
Employee Count
-
Acquired by
Castle Biosciences
(Apr 04, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AltheaDx
AltheaDx offers a comprehensive portfolio of products and services, including IDgenetix, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and DecisionDx-UM. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Analyzes genes to personalize mental health medications and predict responses.
Evaluates melanoma risk and guides treatment decisions based on genetic profiling.
Assists in assessing squamous cell carcinoma prognosis and management options.
Predicts cancer risk in gastroenterology through gene expression analysis.
Supports uveal melanoma diagnosis and metastatic risk evaluation.
Unlock access to complete
Unlock access to complete
Funding Insights of AltheaDx
AltheaDx has successfully raised a total of $94.73M across 14 strategic funding rounds. The most recent funding activity was a Series D round of $3.73 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Series D — $3.7M
-
First Round
First Round
(19 Aug 2009)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2020 | Amount | Series D - AltheaDx | Valuation |
investors |
|
| Oct, 2019 | Amount | Series D - AltheaDx | Valuation |
investors |
|
| Jan, 2019 | Amount | Series D - AltheaDx | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AltheaDx
AltheaDx has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Castle Biosciences, WuXi AppTec and 6 Dimensions Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life-Sciences focused early and growth stage VC firm funding companies in China & the US
|
Founded Year | Domain | Location | |
|
Private equity and hedge fund investments in healthcare are managed.
|
Founded Year | Domain | Location | |
|
Investment in conscious healthcare businesses is facilitated by ALMA.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AltheaDx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AltheaDx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Altheadx Comparisons
Competitors of AltheaDx
AltheaDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| domain | founded_year | HQ Location |
Diagnostic services are provided through laboratories and radiology units.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Altheadx
Frequently Asked Questions about AltheaDx
When was AltheaDx founded?
AltheaDx was founded in 2009.
Where is AltheaDx located?
AltheaDx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is AltheaDx a funded company?
AltheaDx is a funded company, having raised a total of $94.73M across 14 funding rounds to date. The company's 1st funding round was a Series D of $1.68M, raised on Aug 19, 2009.
What does AltheaDx do?
AltheaDx, Inc. provides molecular diagnostics and PCR-based services. It offers molecular biomarker discovery, assay development, assay validation, and prospectiveretrospective clinical trial testing services. The company also provides gene expression and genotyping analysis for pre-clinical and clinical applications. In addition, it offers discovery services, such as microarray analysis, real-time PCR, next-gen sequencing, quantitative PCR, mutation scanning, data analysis, race assay, and therapeutic siRNA; and diagnostic development services. Further, the company provides clinical trial services, such as enhanced clinical trial, predictive drug response, patient stratification and monitoring.
Who are the top competitors of AltheaDx?
AltheaDx's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
What products or services does AltheaDx offer?
AltheaDx offers IDgenetix, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and DecisionDx-UM.
Who are AltheaDx's investors?
AltheaDx has 6 investors. Key investors include Castle Biosciences, WuXi AppTec, 6 Dimensions Capital, Ally Bridge Group, and ALMA Life Sciences.